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Abstract
Here we describe a middle aged-woman who had septic shock caused by a strain 
of Pseudomonas aeruginosa carrying derepressed AmpC hyper-producing genes. 
This was brought into view when the strain located in pipracillin/tazobactam area 
was exposed on agar plate to imipenem by diffusion causing “D-phenomena”. 
Clinicians and microbiologists have to be aware of this phenomenon for a better 
choice of antimicrobials in treating their patients.
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Introduction
Pseudomonas aeruginosa is a ubiquitous nosocomial patho-
gen affecting compromised hosts. It causes different infec-
tions that occur mostly in intensive care units, such as ventila-
tor-associated pneumonia (VAP), surgical site infections (SSI), 
urinary tract infections (UTI) and blood stream infections (BSI); 
also it may cause nosocomial outbreaks with multiple sites 
infections (1, 2). Rarely does it cause community-acquired 
infections in adult and pediatric populations such as com-
munity-acquired pneumonia, blood stream infections, urinary 
tract infections, and skin-and-skin structures infections (3, 4, 
5, 6). Treating P. aeruginosa infections may be problematic 
as it may adopt one or combination of several mechanisms 
of resistance against several antimicrobials, including  intrin-
sic and  acquired ones; such adoption made the pathogen 
able to deactivate some antimicrobials leading to therapeutic 
failures.  Among resistance mechanisms that P. aeruginosa 
adopts are efflux pumps, Opr D porin, ESBL, metallobeta-
lactamases and class 1 AmpC β-lactamase, the later may be 
expressed at low levels and may be hyper-produced (7, 8, 9, 
10). Hyper-production of class 1 AmpC β-lactamase by P. ae-
ruginosa disqualifies some useful antimicrobials employed for 
use in the treatment of serious infections (1, 9). 
Here we discuss a case of an intractable shock in a young 
woman. Surgical site and blood cultures repeatedly grew P. 
aeruginosa. Moreover, it showed inducible resistant mutants 
to pipracillin/tazobactam on agar plate when it was placed in 
proximity to imipenem, this appeared as straightening of the 
clear zone in pipracillin/tazobactam zone facing imipenem 
and appearing as D-phenomena (Figure 1).
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Case
A 51 years old  Jordanian woman with past medical history 
of hypertension, she was admitted in a private Hospital, Am-
man - Jordan in January 2012 as she presented to the surgical 
department for hernia repair and  abdominoplasty.  On her 
first postoperative day  she  collapsed and coded; CPR was 
done for 15 minutes and was transferred to the ICU for me-
chanical ventilation, later noted to have suffered from brain 
damage, and she remained in hospital few months. During 
her prolonged hospital stay, earlier to her demise, she de-
veloped an intractable shock. She ran a stormy course with 
poor Glasgow scale, ABGs showed acidosis; pH < 6.9, pCO2 
68  mmHg, pO2 67mmHg. Hemoglobin was 13.2 gm/dl, 
dropped to 5.4 gm/dl. Brain MRI showed acute infarction in 
basal ganglia, brain stem, thalami, posterior limbs of inter-
nal capsule and occipital lobes. Later, a follow up brain MRI 
showed massive brain edema and hemorrhages, and substan-
tial atrophy in both hemispheres. Endoscopy showed no G.I. 
hemorrhage, thirteen units of packed RBCs and seven units 
of  fresh frozen plasma were administered. Surgical site and 
blood cultures repeatedly grew P. aeruginosa. In addition, pus 
culture from the surgical site grew MRSA and Acinetobacter 
species.  She  was treated with several antipseudomonal 
agents including meropenem and  pipracillin/tazobactam. 
The patient suffered from intractable shock, disseminated 
intravascular coagulation, multi-organ dysfunction, anoxic 
encephalopathy and died.
Microbiology and molecular biological isolation 
of Pseudomonas aeruginosa
Blood was  cultured  in Vitack II ARD blood culture bottles 
(BioMérieux SA. F-69280 Marcy l’Etoile, France) then spread 
on different plates (as in pus) on  blood-agar, chocolate-
agar,  Mac-Conkey  agar and SAB-agar plates, plates were 
incubated  in aerobic and anaerobic environment, and incu-
bated in thioglycolate for growth augmentation, and kept up 
to five days. Chocolate agar plates were incubated in CO2 en-
vironment for twenty-four hours. Microorganisms were iden-
tified  by colony morphology (shape, color, size) and gram 
stain, gram-negative bacteria grew on selective agar plate 
were lactose fermenter (LF) or non-fermenter (NLF) and pro-
cessed by the automated Viteck II (BioMérieux SA. F-69280 
Marcy l’Etoile, France). E. coli ATCC 25922 and P. aerugino-
sa ATCC 25423 were used as Controls. Kirby-Bauer antibiotic 
disk diffusion used to estimate sensitivity to that particular an-
tibiotic using standard inoculum. In general, larger zones cor-
relate with smaller minimum inhibitory concentration (MIC) 
of the tested antibiotic.
Blood-isolate of P. aeruginosa grown on Muller Hinton agar 
showed D-phenomena by placing imipenem disk next to pip-
racillin/ tazobactam disk, its diffusion toward pipracillin/tazo-
bactam zone induced hyper-production of resistant mutants, 
usually chromosomally mediated derepressed mutants that 
carry AmpC β-lactamase (11, 12).
Figure 1 showed that P. aeruginosa strain isolated from our 
case carry an unreported genome sequence when compared 
with gene bank.
DNA Isolation and Amplification
DNA was isolated from cultivated bacteria using the phenol/
chloroform extraction technique. PCR amplification was done 
using specific Primers for P. aeruginosa. PCR Reaction mix-
tures (100 μl) were as follows:-10 mM Tris-HCl, pH 8.3, 50 
mM KCl, 2.5 mM MgCl2, 200 μM (each) dATP, dCTP, dGTP 
Strain name:  Pseudomonas aeruginosa PA7, g.5505076C>T, p.Asp237Asn
Missense GAC(Asp) -> AAC(Asn)
Reference: gctggtgctggatctctagt C ggcggcgacgtcgccgtgaa
Query (isolated Pseudomonas): gctgctgctggatctctagt T cgcagaggtgtcgccgtgga
Protein changes as a phenotype that lead to the inducible resistance is:  p.Ala235Ser
Figure 1.  Sequence of the blood-isolated 
Pseudomonas aeruginosa. It 
showed a unique sequence 
which was not found in the 
genetic bank found at: http://
www.pseudomonas.com/
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and dTTP; 1.25 U of Taq DNA polymerase (Amplitaq; Perkin 
Elmer), 0.1 μM of the each set of forward Primers and reverse 
primers which are specific for P. aeruginosa. 
The reaction mixtures were subjected to the following empiri-
cally optimized thermal cycling parameters in a Perkin Elmer 
2400 thermocycler following a “hot start”: 96°C for 5 min 
followed by 40 cycles at 96°C for 1 min, 55°C for 1 min, 
72°C for 1 min, followed by a final extension at 72°C for 10 
min. P. aeruginosa ATCC 27853 DNA control and multiple 
negative controls were included in every set of PCR reactions.
Sequencing
Purification of PCR product was done using ExoSAP. Sequenc-
ing of the bacteria was conducted using Sanger method 
(big dye terminator reaction V3.0 (applied biosystems)) for 
sequencing of the forward and reverse primers, reading of 
the sequence done on ABI 310 genetic analyzer System. The 
subsequent sequence was compared to normal bacterial se-
quence found at gene bank website (http://www.pseudomo-
nas.com/) with no previously matched sequence.
 
Discussion
A common mechanism for the development of resistance to 
penicillins like piperacillin and cephalosporins (mostly ceftazi-
dime) is a selective mutation causing the hyper-production of 
the chromosomally mediated cephalosporinase AmpC. AmpC 
β-lactamase gene is present in most Enterobacteriaceae, P. 
aeruginosa and other non-fermenting gram-negative bacilli. 
AmpC is hyper-produced when suppression or inactivation 
of AmpD and AmpE occur. During treatment with β-lactams, 
resistant mutants showing constitutive high levels of AmpC 
production are frequently selected, leading to therapeutic 
failure which in turn prohibits the use of antimicrobial agents 
such as pipracillin/tazobactam and ceftazidime (1).
In our case P. aeruginosa showed a phenomenon of hyper-
production of the chromosomally-mediated β-lactamase 
(AmpC), when it was exposed to a carbapenem (here me-
ropenem). Meanwhile, Pseudomonas aeruginosa may acquire 
resistance to carbapenems by porin loss (OprD) and proteins 
involved in four efflux systems (mexA, mexC, mexE, and 
mexX) (9). Our patient suffered of intractable shock though 
she was on several β-lactam antimicrobials and later merope-
nem. During β-lactams and later carbapenems treatment, 
blood cultures revealed acquired inducible P. aeruginosa 
mutants carrying AmpC which lead to hyper-production of 
AmpC β-lactamase. This lead to treatment failure of the last 
(non carbapenem) β-lactams that were administered. Nearly 
before her demise meropenem was re-administered when 
mortality was looming.
This case rings a bell for infectious diseases practitioner 
and clinical microbiologists to suspect resistance mecha-
nisms by being aware of the D-phenomena caused by 
AmpC  β-lactamase hyper-production. When patients are 
initially exposed to a carbapenem as a therapeutic regimen 
for treating serious gram-negative infections, it may not be 
wise to change back to other β-lactams like ceftazidime or 
pipracillin/tazobactam, unless vigilance to pathogen diagno-
sis and susceptibility is sought. Even carbapenems may suffer 
from resistance based on the presence of AmpC and OprD 
(D2 porin protein) loss or efflux mechanisms (14). This pattern 
of resistance has to be communicated to other health-care 
providers; to be aware that carbapenems may select hyper-
production of AmpC  β-lactamase in gram-negative bacilli; 
therefore, other non-carbapenem β-lactams regimen cannot 
be an option.
As a reminder, a similar well known “D-phenomenon” occurs 
in S. aureus when Clindamycin disk is placed in proximity to 
Erythromycin disk on Muller Hinton agar. Here Erythromycin 
induces resistant mutants in the clindamycin zone (15, 16).
In conclusion, microbiologists and clinicians have to be aware 
of the possibility of AmpC  β-lactamase hyper-production 
should a D-phenomena is detected by clinical laboratory; 
when patients have clinical deterioration, especially when 
carbapenem containing regimen preceded other β–lactams 
antimicrobials, as commonly practiced in intensive care units, 
where combinations and hopping to other antimicrobials fre-
quently occur.
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